Reports of rare clotting and bleeding disorders in younger adults, some fatal, led a number of countries to limit the vaccine’s use to older people, and a few to drop it altogether.
People receiving the COVID vaccine made by Oxford-AstraZeneca, also known as Covishield in India, had a slightly increased risk of a bleeding disorder and possibly other rare blood problems, researchers reported Wednesday.
The findings, from a study of 2.53 million adults in Scotland who received their first doses of either the AstraZeneca vaccine or the one made by Pfizer-BioNTech, were published in the journal Nature Medicine. About 1.7 million of the shots were the AstraZeneca vaccine.
The study found no increased risk of the blood disorders with the Pfizer-BioNTech vaccine.
Link For Original Site:
